---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-337944"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2026-08-06T20:05:18+00:00"
generated_at: "2026-08-06T20:06:20.312779+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q2 2026 net loss of $4.8M; advances gamma-delta TCE platform with in vivo data expected H2 2026

## Summary
- Net loss of $4.8M ($0.25 per share) in Q2 2026, improved from $5.1M ($1.24) in Q2 2025.
- Cash of $18.0M at June 30, 2026, up from $13.2M a year earlier.
- DeltEx DRI in GBM: mOS >19.5 months, mPFS 13.0 months vs 6.6 months SOC.
- INB-619 gamma-delta TCE platform advancing; initial in vivo data expected H2 2026.
- Peer-reviewed publication in JCO and updated data at ASCO 2026 for DeltEx DRI in GBM.

## SEC filing metadata
- accession: 0001193125-26-337944
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2026-08-06T20:05:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/0001193125-26-337944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/inab-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-337944
- JSON: https://secwatch.observer/filing/0001193125-26-337944.json
- Plain text: https://secwatch.observer/filing/0001193125-26-337944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.